---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-26-000105"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2026-09-29T11:33:10+00:00"
generated_at: "2026-10-12T13:42:05.619562+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cartesian's Descartes-08 retreatment cuts MG-ADL 6.6 points at Month 12; no new safety signals; Phase 3 AURORA data 1Q27

## Summary
- In 5 retreated MG patients, mean MG-ADL fell 6.6 (±4.2) points and MGC fell 15 (±6.2) points from baseline at Month 12 after retreatment.
- Median time from initial treatment completion to first retreatment was 16.6 months; all patients had clinically meaningful MGC (≥3) and MG-ADL (≥2) reductions.
- No serious adverse events during retreatment; no cases of CRS, ICANS, cytopenias, or hypogammaglobulinemia; adverse events were transient and mild.
- Phase 3 AURORA topline data expected 1Q27; BLA filing in MG expected mid-2027; Descartes-08 has RMAT and Orphan Drug designations and FDA SPA agreement.
- Patients had mean disease duration of 13 years and extensive prior treatment histories.

## SEC filing metadata
- accession: 0001453687-26-000105
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2026-09-29T11:33:10+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/0001453687-26-000105-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000105/rnac-20260929.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-26-000105
- JSON: https://secwatch.observer/filing/0001453687-26-000105.json
- Plain text: https://secwatch.observer/filing/0001453687-26-000105.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.